Tien S Dong1, John P Vu2,3, Suwan Oh2, Daniel Sanford2, Joseph R Pisegna2, Patrizia Germano4,5,6. 1. The Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. tsdong@mednet.ucla.edu. 2. Division of Gastroenterology, Hepatology and Parenteral Nutrition, Department of Medicine and Human Genetics, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 3. AbbVie, Sunnyvale, CA, USA. 4. Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 5. CURE/Digestive Diseases Research Center, Department of Medicine, University of California, Los Angeles, CA, USA. 6. Division of Pulmonary and Critical Care, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Abstract
BACKGROUND: Kisspeptin is a neuropeptide that plays an integral role in the regulation of energy intake and reproduction by acting centrally on the hypothalamus-pituitary-gonadal axis. Our current study explores for the first time the effects of a pharmacological treatment of intraperitoneal kisspeptin-10 on murine feeding behavior, respirometry parameters, energy balance, and metabolic hormones. METHODS: Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle. Microstructure of feeding and drinking behavior, respirometry gases, respiratory quotient (RQ), total energy expenditure (TEE), metabolic hormones, oral glucose tolerance, and lipid profiles were measured. RESULTS: Intraperitoneal treatment with kisspeptin-10 caused a significant reduction in food intake, meal frequency, meal size, and eating rate. Kisspeptin-10 significantly decreased TEE during both the dark and light phase cycles, while also increasing the RQ during the dark-phase cycle. In addition, mice injected with kisspeptin-10 had significantly higher plasma levels of insulin (343.8 pg/ml vs. 106.4 pg/ml; p = 0.005), leptin (855.5 pg/ml vs. 173.1 pg/ml; p = 0.02), resistin (9411.1 pg/ml vs. 4116.5 pg/ml; p = 0.001), and HDL (147.6 mg/dl vs 97.1 mg/dl; p = 0.04). CONCLUSION: A pharmacological dose of kisspeptin-10 significantly altered metabolism by suppressing food intake, meal size, eating rate, and TEE while increasing the RQ. These changes were linked to increased levels of insulin, leptin, resistin, and HDL. The current results suggest that a peripheral kisspeptin treatment could alter metabolism and energy homeostasis by suppressing appetite, food intake, and fat accumulation.
BACKGROUND:Kisspeptin is a neuropeptide that plays an integral role in the regulation of energy intake and reproduction by acting centrally on the hypothalamus-pituitary-gonadal axis. Our current study explores for the first time the effects of a pharmacological treatment of intraperitoneal kisspeptin-10 on murine feeding behavior, respirometry parameters, energy balance, and metabolic hormones. METHODS: Two groups (n = 16) of age- and sex-matched C57BL/6 wild-type adult mice were individually housed in metabolic cages and intraperitoneally injected with either kisspeptin-10 (2 nmol in 200 µl of saline) (10 µM) or vehicle before the beginning of a dark-phase cycle. Microstructure of feeding and drinking behavior, respirometry gases, respiratory quotient (RQ), total energy expenditure (TEE), metabolic hormones, oral glucose tolerance, and lipid profiles were measured. RESULTS: Intraperitoneal treatment with kisspeptin-10 caused a significant reduction in food intake, meal frequency, meal size, and eating rate. Kisspeptin-10 significantly decreased TEE during both the dark and light phase cycles, while also increasing the RQ during the dark-phase cycle. In addition, mice injected with kisspeptin-10 had significantly higher plasma levels of insulin (343.8 pg/ml vs. 106.4 pg/ml; p = 0.005), leptin (855.5 pg/ml vs. 173.1 pg/ml; p = 0.02), resistin (9411.1 pg/ml vs. 4116.5 pg/ml; p = 0.001), and HDL (147.6 mg/dl vs 97.1 mg/dl; p = 0.04). CONCLUSION: A pharmacological dose of kisspeptin-10 significantly altered metabolism by suppressing food intake, meal size, eating rate, and TEE while increasing the RQ. These changes were linked to increased levels of insulin, leptin, resistin, and HDL. The current results suggest that a peripheral kisspeptin treatment could alter metabolism and energy homeostasis by suppressing appetite, food intake, and fat accumulation.
Authors: Shaoqi Xu; Mei Wang; Ya Li; Ni Tang; Xin Zhang; Hu Chen; Shupeng Zhang; Yanling Liu; Jun Wang; Defang Chen; Zhiqiong Li Journal: Fish Physiol Biochem Date: 2022-02-20 Impact factor: 2.794
Authors: Nayeli Escudero Castelán; Dean C Semmens; Luis Alfonso Yañez Guerra; Meet Zandawala; Mario Dos Reis; Susan E Slade; James H Scrivens; Cleidiane G Zampronio; Alexandra M Jones; Olivier Mirabeau; Maurice R Elphick Journal: BMC Biol Date: 2022-08-24 Impact factor: 7.364
Authors: Lisa Yang; Lysia Demetriou; Matthew B Wall; Edouard G Mills; Victoria C Wing; Layla Thurston; Caroline N Schaufelberger; Bryn M Owen; Ali Abbara; Eugenii A Rabiner; Alexander N Comninos; Waljit S Dhillo Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 6.134